Statistics

Total Visits

Views
A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women 165

Total Visits per Month

November 2023 December 2023 January 2024 February 2024 March 2024 April 2024 May 2024
A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women 12 8 16 3 6 11 9

File Downloads

Views
hdl_138889.pdf 35
hdl_138889.pdf 20

Top Country Views

Views
United States 51
Australia 37
Vietnam 9
China 7
Singapore 7
Hong Kong SAR China 6
Belgium 5
Ireland 5
Bulgaria 2
Sweden 2

Top City Views

Views
Ashburn 11
New York 10
Hanoi 9
Boardman 6
Central 6
Brussels 5
Clonee 5
Singapore 5
Brisbane 3
Sydney 3